Gene therapy vs. observation for intermediate risk bladder cancer
Treatments studied
Part of Cancer, Kidney & urinary clinical trials.
This trial tests a new gene therapy called nadofaragene firadenovec versus just watching and waiting (observation) for people with a specific type of bladder cancer that hasn't grown into the muscle. The goal is to see if the gene therapy can help keep the cancer from coming back.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a type of bladder cancer called intermediate risk non-muscle invasive bladder cancer (IR NMIBC).
- You had a procedure called a TURBT (transurethral resection of bladder tumor) within the last 60 days.
- Your tumor is one of these types: low-grade Ta that came back within a year, a low-grade Ta larger than 3 cm, multiple low-grade Ta tumors, a single high-grade Ta 3 cm or smaller, or low-grade T1.
- You do not have high-risk or low-risk bladder cancer, and your cancer has not spread to muscle or other parts of the body.
- You have not had BCG treatment failure or other high-risk features like carcinoma in situ (CIS).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial compares a gene therapy (nadofaragene firadenovec) against standard care for people with an early-stage bladder cancer that has not responded to BCG. The goal is to see if this treatment is more effective and possibly helps avoid bladder removal.
This trial tests a gene therapy called nadofaragene firadenovec, given directly into the bladder, either alone or with chemo or immunotherapy. It's for people with high-grade bladder cancer that hasn't gone away after BCG treatment.
This trial tests a new drug, nadofaragene firadenovec, which uses a harmless virus to deliver a signal that helps your immune system fight low-grade cancer in the upper part of the urinary tract (the kidney area). It's given directly into the kidney through a small tube, and may avoid more invasive surgery.
This trial tests a new treatment combination before bladder removal surgery for muscle-invasive bladder cancer. It uses a special virus-delivered gene therapy (nadofaragene firadenovec) plus two chemotherapy drugs (cisplatin and gemcitabine) and an immunotherapy drug (durvalumab) to try to shrink the tumor and improve outcomes.
This trial tests a new virus-based medicine, cretostimogene grenadenorepvec, given directly into the bladder for people with high-risk non-muscle-invasive bladder cancer. It may help prevent the cancer from coming back, especially for those who have not had BCG treatment or whose cancer did not respond to BCG.
This trial tests a new treatment called NDV01 KIT for people with high-grade non-muscle invasive bladder cancer that hasn't gotten better after BCG therapy. It's for those who cannot or choose not to have their bladder removed.
Hear when a new Intermediate Risk Non-Muscle Invasive Bladder Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.